Protein Therapeutics Market Thumbnail Image

2022

Protein Therapeutics Market

Protein Therapeutics Market Size, Share, Competitive Landscape and Trend Analysis Report by Product and Application : Global Opportunity Analysis and Industry Forecast, 2021-2030

LS : Pharmaceuticals

Select an option
Author's: Shraddha Mali| Madhuvanti Divekar | Roshan Deshmukh
Publish Date:

Get Sample to Email

Protein Therapeutics Market Overview 2030

The global protein therapeutics market size was valued at $283.64 Billion in 2020, and is estimated to reach $566.66 Billion by 2030, growing at a CAGR of 7.1% from 2021 to 2030. Therapeutic proteins are the medicines that are genetically engineered versions of naturally occurring human proteins. They can be used to replace a protein that is abnormal or deficient in a specific disease. They can also supplement supply of a beneficial protein, which can help mitigate effects of disease or chemotherapy. Genetically engineered proteins can be designed to closely resemble natural proteins they replace or they can be enhanced by addition of sugars or other molecules that extend the protein's activity duration. 

Therapeutic protein drugs are a type of medicine that are used to treat a variety of diseases such as cancer, metabolic, immunological, hematological, hormonal, genetic, infectious diseases, and others. These drugs have the potential to significantly improve human health. In principle, protein therapy is similar to gene therapy; which involves protein delivery in specific amounts to the body to facilitate precise functioning of different glands and other organs in the body

	Protein-Therapeutics-Market

Growth of the protein therapeutics market is majorly driven by rise in prevalence of chronic diseases and development of plasma-derived therapies. Increase in prevalence of various diseases such as cancer, metabolic disorders, genetic disorders, and immunological diseases are expected to propel demand for protein therapeutics. In addition, according to the World Health Organization (WHO), cancer is a leading cause of death worldwide, and cancer cases are expected to increase significantly in the future. Thus, rise in prevalence of cancer is anticipated to drive the protein therapeutics market.

In addition, rise in proteomics research has further led to rise in the market growth. Protein microarray allows classification of proteins in a parallel and high-throughput way. The possibility of performing numerous assays in one small plate saves time of researchers and curbs the experiment cost. Growth in proteomic research is expected to lead to an increase in emergence of new protein drugs, which can further be used for treatment of various diseases.

However, high production costs required for developing as well as manufacturing protein-based therapeutics is expected to restrain growth of the market. Conversely, considerable rise in healthcare expenditure globally has led to the protein therapeutics market growth. Emerging economies of Asia-Pacific and LAMEA possess high potential for protein therapeutics. Growth in awareness regarding chronic diseases and use of proteins for treatment of these diseases has resulted in regulatory authorities in this region to take key decisions to improve legislations of protein therapeutics. Increase in geriatric population, growth in number of chronic diseases, and high requirement for protein therapeutics are expected to drive demand for these products over the next few years. In addition, emerging nations need to focus on cost-effectiveness and scalability to cater to the needs of the rising patient pool.

What is the Impact of COVID-19 Pandemic on the Protein Therapeutics Market?

In addition, the COVID-19 outbreak is anticipated to have a positive impact on the protein therapeutics market. A huge number of clinics and hospitals across the globe were restructured to increase the hospital capacity for patients diagnosed with COVID-19. Non-essential procedures took a potential backlog, owing to rapid rise in COVID-19 cases. The lockdown led to disruption of manufacturing and transportation of healthcare essentials. However, diagnosis and treatment of COVID-19 and other diseases increased significantly during the pandemic, thus demand for protein based therapeutic drugs was increased.

Protein Therapeutics Market Segmentation

The protein therapeutics market is segmented into product, application, and region. On the basis of product, it is classified into monoclonal antibodies, insulin, fusion protein, erythropoietin, interferon, human growth hormone, and follicle-stimulating hormone. On the basis of application, it is classified into metabolic disorders, immunologic disorders, hematological disorders, cancer, hormonal disorders, genetic disorders, and others.

Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Protein Therapeutics Market
By Product
Your browser does not support the canvas element.

Monoclonal Antibodies holds a dominant position in 2020 and would continue to maintain the lead over the forecast period.

Segment Review

On the basis of product, the monoclonal antibodies segment dominated the market in 2020, and is expected to remain dominant during the forecast period, owing to its wide range of availability, importance and applicability of these products in the treatment of different chronic disorders.

By application, the metabolic disorders segment dominated the market in 2020, and is expected to remain dominant during the forecast period, owing to requirement for quality drugs and versatile therapies for disease treatment, especially diabetes, which is expected to boost the growth of this segment.

Protein Therapeutics Market
By Application
Your browser does not support the canvas element.

Cancer segment is projected as one of the most lucrative segment.

North America exhibited the global protein therapeutics market share in 2020, and is anticipated to remain dominant during the forecast period. This is attributed to increase in prevalence of chronic diseases, adoption of technologically advanced treatments, presence of key players, and rise in healthcare expenditure in the region. However, Asia-Pacific is anticipated to witness notable growth, owing to increase in R&D activities, increase in disposable incomes, and improvement in patient awareness toward protein therapeutics. Moreover, India and China are expected to grow at high CAGR in the Asia-Pacific protein therapeutics market.   

Protein Therapeutics Market
By Region
2030
North America 
Europe
Asia-Pacific
LAMEA

Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 8.7% during the forecast period.

Key Benefits for Stakeholders

  • The study provides an in-depth analysis of the protein therapeutics market, current trends, and future estimations to elucidate the imminent investment pockets.
  • It presents a quantitative analysis of the market from 2021 to 2030 to enable stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the market based on procedures and services assists to understand the trends in the industry.
  • Key players and their strategies are thoroughly analyzed to understand the competitive outlook of the protein therapeutics market.

Protein Therapeutics Market Report Highlights

Aspects Details
icon_5
By PRODUCT
  • Monoclonal Antibodies
  • Insulin
  • Fusion Protein
  • Erythropoietin
  • Interferon
  • Human Growth Hormone
  • Follicle Stimulating Hormone
icon_6
By APPLICATION
  • Metabolic Disorders
  • Immunologic Disorders
  • Hematological Disorders
  • Cancer
  • Hormonal Disorders
  • Genetic Disorders
  • Others
icon_7
By Region
  • North America  (U.S, Canada, Mexico)
  • Europe  (UK, Germany, France, Spain, Italy, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, Australia, South Korea, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
icon_8
Key Market Players

Amgen Inc., Novo Nordisk AS, Merck and Co., Inc., Sanofi, Johnson and Johnson (Janssen Pharmaceuticals), Pfizer Inc., Abbott Laboratories, Eli Lilly And Company, Baxter International Inc., F. Hoffmann La Roche Ltd

Analyst Review

This section provides opinions of top-level CXOs in the biotechnological & pharmaceutical industry. According to CXOs, protein therapeutics have positively impacted diverse fields of disease treatment and prognosis. Diseases that were otherwise debilitating and life threatening can be managed through administration of these drugs. These drugs have also contributed significantly in diagnosis and prevention of oncologic, metabolic, immunologic, genetic, and other chronic diseases.

CXOs further state that protein therapeutics are expected to witness high adoption rate with increase in distinct indications and interventions, such as lymphomas, diabetes, hepatitis, and leukemia. The global protein therapeutics market has witnessed significant momentum in the healthcare industry and pharmaceutical sector, owing to favorable government policies, conducive regulations abiding protein therapeutics, and growth in proteomics research. However, high development & manufacturing cost, high treatment costs per patient, stringent government regulations, and complex reimbursement scenario restrict the market growth.

North America is expected to witness highest growth, in terms of revenue during the forecast period, owing to rise in chronic diseases, adoption of technologically advanced treatments in this region, presence of key players, and advancements in healthcare investments. However, Asia-Pacific, is expected to grow significantly, owing to its high population base, surge of diseases, increase in disposable incomes, and improvement in patient awareness toward protein therapeutics.

 

Author Name(s) : Shraddha Mali| Madhuvanti Divekar | Roshan Deshmukh
Frequently Asked Questions?

The total market value of protein therapeutics market is $283.64 billion in 2020.

The forecast period for protein therapeutics market is 2021 to 2030

The market value of protein therapeutics market in 2021 is $304.52 billion.

The base year is 2020 in protein therapeutics market

Top companies such as Abbott Laboratories, Amgen Inc., Baxter International Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson (Janssen Pharmaceuticals), Merck & Co., Inc., Novo Nordisk A/S, Pfizer Inc., and Sanofi, held a high market position in 2020.

Monoclonal antibodies segment dominated the global market in 2020, and expected to continue this trend throughout the forecast period due to availability of wide range of protein therapeutics based on monoclonal antibodies and applicability of these products in the treatment of different chronic disorders is expected to drive the segment

Increase in prevalence of chronic diseases, rising patient pool and various technological advancements in protein therapeutics is anticipated to drive the market in the forecast period.

North America is projected to account for a major share of the global protein therapeutics market during the forecast period. U.S. dominated the North America protein therapeutics market owing to increased chronic chrnic diseases, adoption of technologically advanced therapies and health awareness across the country.

Loading Table Of Content...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?

Protein Therapeutics Market

Global Opportunity Analysis and Industry Forecast, 2021-2030